Tumor-derived lactate drives transcriptional reprogramming (CCL2, ARG1, IL10, S100A9) in TAMs via the ENSA-K63la/STAT3-pY705 axis, promoting an immunosuppressive environment and immunotherapy resistance. Here, S100A9 is linked to neoplasm.